GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Buyback Yield %

ME Therapeutics Holding (XCNQ:METX) Buyback Yield % : 0.00 (As of Jun. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

ME Therapeutics Holding's current buyback yield was 0.00%.

ME Therapeutics Holding Buyback Yield % Historical Data

The historical data trend for ME Therapeutics Holding's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Buyback Yield % Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Buyback Yield %
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Buyback Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of ME Therapeutics Holding's Buyback Yield %

For the Biotechnology subindustry, ME Therapeutics Holding's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Buyback Yield % falls into.


ME Therapeutics Holding Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

ME Therapeutics Holding's Buyback Yield for the fiscal year that ended in Aug. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.116) / 0
=N/A%

ME Therapeutics Holding's annualized Buyback Yield for the quarter that ended in Feb. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 103.9918
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Feb. 2024) data.

ME Therapeutics Holding Buyback Yield % Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Buyback Yield %
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines